Azithromycin; Clarithromycin; Erythromycin/Selected QT Prolonging Agents
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Your antibiotic can affect your heart's rhythm. Other drugs can have the same effect.
What might happen:
Taking your antibiotic with other agents that can affect your heart rhythm may increase your risk of irregular heartbeat, which may be life-threatening.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to perform an electrocardiogram (ECG) on you to check your heart's rhythm. Let your doctor know right away if you notice an irregular heartbeat or have any dizziness or fainting episodes.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Zithromax (azithromycin oral) US prescribing information. Pifzer Labs February 19, 2013.
2.Biaxin (clarithromycin) US prescribing information. AbbVie, Inc. September, 2013.
3.E.E.S. (erythromycin ethylsuccinate) US prescribing information. Arbor Pharmaceuticals, Inc. January, 2012.
4.Ketek (telithromycin) US prescribing information. Sanofi-Aventis U.S. LLC December, 2010.
5.Saphris (asenapine) US prescribing information. Schering Corporation October, 2011.
6.Procoralan (ivabradine hydrochloride) summary of product characteristics. Servier December, 2005.
7.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories January, 2013.
8.Rythmol (propafenone hydrochloride) US prescribing information. Abbott Laboratories March, 2013.
9.Javlor (vinflunine ditartrate) UK Summary of Product Characteristics. Pierre Fabre Limited September 21, 2009.
10.Clopixol (zuclopenthixol acetate) UK summary of product characteristics. Lundbeck House October 24, 2008.
11.Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, Philippides GJ, Roden DM, Zareba W. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010 Mar 2;55(9):934-47.
12.The University of Arizona Center for Education and Research of Therapeutics. Drugs with Risk of Torsades de Pointes and Drugs with Possible Risk of Torsades de Pointes. Available at:http://www.crediblemeds.org/. Updated March 14, 2013.
13.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.